RISK-BENEFIT RATIO OF MODERN ANTIFUNGAL THERAPY - FOCUS ON HEPATIC REACTIONS

被引:72
作者
HAY, RJ
机构
关键词
D O I
10.1016/S0190-9622(08)81838-5
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
The purpose of this article is to review the risk/benefit ratio of the oral antifungals: griseofulvin, ketoconazole, fluconazole, itraconazole, and terbinafine. The reported side effects of each drug have been listed with particular emphasis on the possibility of hepatic damage. All oral antifungal agents cause minor gastrointestinal upset, as well as headache and skin reactions. There is also a rare incidence of reversible hepatic damage. Although the incidence of abnormal liver function tests from oral antifungal therapy is extremely low, patients should be advised to inform their physician if any warning symptoms are noticed.
引用
收藏
页码:S50 / S54
页数:5
相关论文
共 17 条
[1]   FLUCONAZOLE-INDUCED THROMBOCYTOPENIA [J].
AGARWAL, A ;
SAKHUJA, V ;
CHUGH, KS .
ANNALS OF INTERNAL MEDICINE, 1990, 113 (11) :899-899
[2]  
BREINSTRUP AH, 1966, UGESKRIFT LAEGER, V128, P145
[3]  
Cauwenbergh G., 1985, Oral therapy in dermatomycoses: a step forward, P27
[4]  
CHIPRUT RO, 1976, GASTROENTEROLOGY, V70, P1141
[5]  
CLANAN CD, 1960, T STJOHNS HOSP DERM, V45, P54
[6]  
CLISSOLD SP, 1990, KETOCONAZOLE TODAY, P77
[7]  
GANER A, 1987, REV INFECTIOUS DI S1, V9, P77
[8]   LOSS OF TASTE AND TERBINAFINE [J].
JUHLIN, L .
LANCET, 1992, 339 (8807) :1483-1483
[9]   HEPATIC-INJURY ASSOCIATED WITH ITRACONAZOLE [J].
LAVRIJSEN, APM ;
BALMUS, KJ ;
NUGTERENHUYING, WM ;
ROLDAAN, AC ;
VANTWOUT, JW ;
STRICKER, BHC .
LANCET, 1992, 340 (8813) :251-252
[10]  
LEWIS JH, 1984, GASTROENTEROLOGY, V86, P503